首页 | 本学科首页   官方微博 | 高级检索  
     

曲安奈德在增生性玻璃体视网膜病变中应用的研究进展
引用本文:郭海霞,于金国,颜华. 曲安奈德在增生性玻璃体视网膜病变中应用的研究进展[J]. 眼科新进展, 2021, 0(10): 992-995. DOI: 10.13389/j.cnki.rao.2021.0209
作者姓名:郭海霞  于金国  颜华
作者单位:300052 天津市,天津医科大学总医院
摘    要:增生性玻璃体视网膜病变(PVR)在孔源性视网膜脱离、眼外伤以及玻璃体切割手术后均可能发生。曲安奈德(TA)作为一种长效糖皮质激素在PVR的预防和抑制中具有一定的效果。本文就TA在PVR预防和抑制中的分子机制、体外实验、体内实验、临床应用进展进行综述,以期为今后TA更好应用提供一定帮助。

关 键 词:增生性玻璃体视网膜病变  曲安奈德  分子机制

Progress of triamcinolone acetonide in the treatment of proliferative vitreoretinopathy
GUO Haixia,YU Jinguo,YAN Hua. Progress of triamcinolone acetonide in the treatment of proliferative vitreoretinopathy[J]. Recent Advances in Ophthalmology, 2021, 0(10): 992-995. DOI: 10.13389/j.cnki.rao.2021.0209
Authors:GUO Haixia  YU Jinguo  YAN Hua
Affiliation:Department of Ophthalmology,General Hospital of Tianjin Medical University, Tianjin 300052,China
Abstract:Occurrence of proliferative vitreoretinopathy (PVR) is common in rhegmatogenous retinal detachment, ocular trauma and post pars plana vitrectomy. As a long-acting glucocorticoid, triamcinolone acetonide (TA) has been proven to prevent and inhibit PVR effectively. Hence, the molecular mechanism, in vitro experiment, in vivo experiment and clinical application of TA in the prevention and inhibition of PVR are reviewed, hoping to promote the better application of TA on ocular diseases in the near future.
Keywords:proliferative vitreoretinopathy   triamcinolone acetonide   molecular mechanism
点击此处可从《眼科新进展》浏览原始摘要信息
点击此处可从《眼科新进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号